Research Reports

Summary

Cardiol Therapeutics announced its year-end 2025 operational update, highlighting accelerated enrollment in the pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis, positive Phase II ARCHER results in acute myocarditis, advancement of the CRD-38 program toward Phase I, U.S. patent protection extension, board strengthening, and a strengthened cash runway into Q4 2027.

Key takeaways

The pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis surpassed 50% patient enrollment, with full enrollment expected in Q2 2026, supporting a potential New Drug Application.

Positive Phase II ARCHER trial results demonstrated CardiolRx™ significantly reduced left ventricular mass in acute myocarditis patients, with data published in ESC Heart Failure.

The CRD-38 program for heart failure advanced toward an Investigational New Drug Application and Phase I clinical development.

The company received a U.S. patent allowance broadly protecting CardiolRx™ and CRD-38 for use in treating cardiac conditions through October 2040.

Dr. Timothy J. Garnett, former Chief Medical Officer of Eli Lilly and Company, was elected to the Board of Directors in May 2025.

Aggregate gross proceeds of approximately $31 million from financings provide a cash runway into Q4 2027.

Full analysis

Cardiol Therapeutics' year-end 2025 update underscores significant clinical and strategic progress across its pipeline. The company's lead candidate, CardiolRx™, is advancing through a pivotal Phase III trial (MAVERIC) for recurrent pericarditis, with enrollment surpassing the halfway mark and on track for completion in Q2 2026. This trial is designed to support a New Drug Application, targeting a market with significant unmet need for a non-immunosuppressive oral therapy. Concurrently, positive Phase II ARCHER trial results for CardiolRx™ in acute myocarditis were published, demonstrating meaningful structural improvements in the heart and providing clinical proof of concept for treating inflammatory cardiac conditions. The company is also progressing its next-generation drug, CRD-38, toward Phase I development for heart failure. Strategically, Cardiol strengthened its intellectual property with a U.S. patent allowance extending protection for its drug candidates through 2040, bolstered its board with the addition of Dr. Timothy Garnett, who brings extensive regulatory and commercialization experience from Eli Lilly, and secured approximately $31 million in financing, extending its cash runway into Q4 2027. These developments collectively position the company to advance toward key value-inflection milestones, including potential regulatory submissions and further clinical development.